Applications of the P50 evoked response to the evaluation of cognitive impairments after traumatic brain injury

Physical Medicine and Rehabilitation Clinics of North America

Volumn 15, Issue 1, 2004, Pages 177-203

  Arciniegas, David B ^a,b   Topkoff, Jeannie L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b HealthONE Spalding Rehabilitation Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE ACETYLTRANSFERASE; DONEPEZIL; GALANTAMINE; NEUROLEPTIC AGENT; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; PSYCHOSTIMULANT AGENT; RIVASTIGMINE; SCOPOLAMINE;

ATTENTION DEFICIT DISORDER; AUDITORY STIMULATION; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; BRAIN INJURY; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE SEVERITY; ENZYME ACTIVITY; EVOKED CORTICAL RESPONSE; HIPPOCAMPUS; HUMAN; MENTAL DISEASE; NEUROBIOLOGY; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PRIORITY JOURNAL; PSYCHOPATHY; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT;

EID: 1142297675     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-9651(03)00104-9     Document Type: Review

References (143)

1. Kraus J.F., Nourjah P. The epidemiology of mild head injury. Levin H.S., Eisenberg H.M., Benton A.L. Mild head injury. 1989;8-22 Oxford University Press, New York.
2. Kraus J.F., Sorenson S.B. Epidemiology. Silver J.M., Yudofsky S.C., Hales R.E. Neuropsychiatry of traumatic brain injury. 1994;3-41 American Psychiatric Press, Washington, DC.
3. Max W., MacKenzie E., Rice D. Head injuries: costs and consequences. J Head Trauma Rehabil. 6:1991;76-91.
4. Annegers J.F., Grabow J.D., Kurland L.T., et al. The incidence, causes, and secular trends in head injury in Olmsted County, Minnesota. Neurology. 30:1980;912-919.
5. Whitman S., Coonley-Hoganson R., Desai B.T. Comparative head trauma experiences in two socioeconomically different Chicago-area communities: a population study. Am J Epidemiol. 119:1984;570-580.
6. Jagger J., Levine J., Jane J., et al. Epidemiologic features of head injury in a predominantly rural population. J Trauma. 24:1984;40-44.
7. MacKenzie E.J., Edelstein S.L., Flynn J.P. Hospitalized head-injured patients in Maryland: incidence and severity of injuries. Md Med J. 38:1989;725-732.
8. Barth J.T., Macciocchi S.N., Giordani B., et al. Neuropsychological sequelae of minor head injury. Neurosurgery. 13:1983;529-533.
9. Rimel R.W., Giordani B., Barth J.T., et al. Disability caused by minor head injury. Neurosurgery. 9:1981;221-228.
10. Rimel R.W., Giordani B., Barth J.T., et al. Moderate head injury: completing the clinical spectrum of brain trauma. Neurosurgery. 11:1982;344-351.
11. Meir M.J., Strauman S., Thompson W.G. Individual differences in neuropsychological recovery: an overview. Meir M.J., Diller L., Benton A.L. Neuropsychological rehabilitation. 1987;71-110 Churchill Livingstone, London.
12. Dikmen S., McLean A. Jr., Temkin N., et al. Neuropsychologic outcome at one-month postinjury. Arch Phys Med Rehabil. 67:1986;507-513.
13. Dikmen S., McLean A., Temkin N. Neuropsychological and psychosocial consequences of minor head injury. J Neurol Neurosurg Psychiatry. 49:1986;1227-1232.
14. Montgomery E.A., Fenton G.W., McClelland R.J., et al. The psychobiology of minor head injury. Psychol Med. 21:1991;375-384.
15. Rutherford W.H., Merret J.D., McDonald J.R. Sequelae of concussion caused by minor head injuries. Lancet. 1:1977;1-4.
16. Rutherford W.H., Merret J.D., McDonald J.R. Symptoms at one year following concussion from minor head injuries. Injury. 10:1979;225-230.
17. Levin H.S., Mattis S.R.R.M., et al. Neurobehavioral outcome following minor head injury: a three-center study. J Neurosurg. 66:1987;234-243.
18. O'Shanick G.J., O'Shanick A.M. Personality and intellectual changes. Silver J.M., Yudofsky S.C., Hales R.E. Neuropsychiatry of traumatic brain injury. 1994;163-188 American Psychiatric Press, Washington, DC.
19. Gronwall D. Cumulative and persisting effects of concussion on attention and cognition. Levin H.S., Eisenberg H.M., Benton A.L. Mild head injury. 1989;153-162 Oxford University Press, New York.
20. Lovell M.R., Franzen M.D. Neuropsychological assessment. Silver J.M., Yudofsky S.C., Hales R.E. Neuropsychiatry of traumatic brain injury. 1994;133-160 American Psychiatric Press, Washington, DC.
21. Spikman J.M., Deelman B.G., Van Zomeren A.H. Executive functioning, attention and frontal lesions in patients with chronic CHI. J Clin Exp Neuropsychol. 22:2000;325-338.
22. Filley C.M. Neurobehavioral anatomy. 1995;University Press of Colorado, Niwot.
23. Lovell M.R., Franzen M.D. Neuropsychological assessment. Silver J.M., Yudofsky S.C., Hales R.E. Neuropsychiatry of traumatic brain injury. 1994;133-160 American Psychiatric Press, Washington, DC.
24. Dixon C.E., Ma X., Marion D.W. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J Neurotrauma. 14:1997;161-169.
25. Whitlock J.A. Brain injury, cognitive impairment, and donepezil. J Head Trauma Rehabil. 1:1999;424-427.
26. Arciniegas D., Adler L., Topkoff J., et al. Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation. Brain Inj. 13:1999;1-13.
27. Ciallella J.R., Yan H.Q., Ma X., et al. Chronic effects of traumatic brain injury on hippocampal vesicular acetylcholine transporter and M2 muscarinic receptor protein in rats. Exp Neurol. 152:1998;11-19.
28. 3H]choline uptake but not extracellular choline levels in rats. Neurosci Lett. 180:1994;127-130.
29. Dixon C.E., Bao J., Johnson K.M., et al. Basal and scopolamine-evoked release of hippocampal acetylcholine following traumatic brain injury in rats. Neurosci Lett. 198:1995;111-114.
30. Dixon C.E., Ma X., Marion D.W. Reduced evoked release of acetylcholine in the rodent neocortex following traumatic brain injury. Brain Res. 749:1997;127-130.
31. Saija A., Hayes R.L., Lyeth B.G., et al. The effect of concussive head injury on central cholinergic neurons. Brain Res. 452:1988;303-311.
32. Schmidt R.H., Grady M.S. Loss of forebrain cholinergic neurons following fluid-percussion injury: implications for cognitive impairment in closed head injury. J Neurosurg. 83:1995;496-502.
33. Dewar D., Graham D.I. Depletion of choline acetyltransferase but preservation of M1 and M2 muscarinic receptor binding sites in temporal cortex following head injury: a preliminary human postmortem study. J Neurotrauma. 13:1996;181-187.
34. Murdoch I., Perry E.K., Court J.A., et al. Cortical cholinergic dysfunction after human head injury. J Neurotrauma. 15:1998;295-305.
35. Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res Brain Res Rev. 21:1995;285-300.
36. Pratap-Chand R., Sinniah M., Salem F.A. Cognitive evoked potential (P300): a metric for cerebral concussion. Acta Neurol Scand. 78:1988;185-189.
37. Rusted J.M., Warburton D.M. Cognitive models and cholinergic drugs. Neuropsychobiology. 21:1989;31-36.
38. Aigner T.G. Pharmacology of memory: cholinergic-glutamatergic interactions. Curr Opin Neurobiol. 5:1995;155-160.
39. Freedman R., Adler L.E., Bickford P., et al. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry. 2:1994;179-192.
40. Freedman R., Adler L.E., Myles-Worsley M., et al. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects: human recordings, computer simulation, and an animal model. Arch Gen Psychiatry. 53:1996;1114-1121.
41. Adler L.E., Hoffer L.D., Wiser A., et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 150:1993;1856-1861.
42. Arciniegas D., Olincy A., Topkoff J., et al. Impaired auditory gating and P50 nonsuppression following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 12:2000;77-85.
43. Arciniegas D.B., Topkoff J.L., Rojas D.C., et al. Reduced hippocampal volume in association with p50 nonsuppression following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 13:2001;213-221.
44. Arciniegas D.B., Topkoff J.L., Anderson C.A., et al. Normalization of P50 physiology by donepezil hydrochloride in traumatic brain injury patients. J Neuropsychiatry Clin Neurosci. 13:2001;140.
45. Arciniegas D.B., Topkoff J.L., Anderson C.A., et al. Low-dose donepezil normalizes P50 physiology in traumatic brain injury patients. J Neuropsychiatry Clin Neurosci. 14:2002;115.
46. Gainotti G. Emotional disorders in relation to unilateral brain damage. Feinberg T.E., Farah M.J. Behavioral neurology and neuropsychology. 1997;691-698 McGraw-Hill Health Professions Division, New York.
47. Cassidy J.W. Neuropathology. Silver J.M., Yudofsky S.C., Hales R.E. Neuropsychiatry of traumatic brain injury. 1994;43-79 American Psychiatric Press, Washington, DC.
48. Hinnant D.W. Neurobehavioral consequences: assessment, treatment, and outcome. Marion D.W. Traumatic brain injury. 1999;187-197 Thieme Medical Publishers, New York.
49. Kraus M.F. Neuropsychiatric sequelae: assessment and pharmacologic intervention. Marion D.W. Traumatic brain injury. 1999;173-186 Thieme Medical Publishers, New York.
50. Rattock J., Ross B.P. Cognitive rehabilitation. Silver J.M., Yudofsky S.C., Hales R.E. Neuropsychiatry of traumatic brain injury. 1994;703-732 American Psychiatric Press, Washington, DC.
51. Whyte J., Hart T., Schuster K., et al. Effects of methylphenidate on attentional function after traumatic brain injury: a randomized, placebo-controlled trial. Am J Phys Med Rehabil. 76:1997;440-450.
52. Plenger P.M., Dixon C.E., Castillo R.M., et al. Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil. 77:1996;536-540.
53. Evans R.W., Gualtieri C.T., Patterson D. Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. J Nerv Ment Dis. 175:1987;106-110.
54. Gualtieri C.T., Evans R.W. Stimulant treatment for the neurobehavioral sequelae of traumatic brain injury. Brain Inj. 2:1988;273-290.
55. Lipper S., Tuchman M.M. Treatment of chronic post-traumatic organic brain syndrome with dextroamphetamine: first reported case. J Nerv Ment Dis. 162:1976;366-371.
56. Tang Y.P., Noda Y., Nabeshima T. Involvement of activation of dopaminergic neuronal system in learning and memory deficits associated with experimental mild traumatic brain injury. Eur J Neurosci. 9:1997;1720-1727.
57. Eghwrudjakpor P.O., Miyake H., Kurisaka M., et al. Central nervous system bioaminergic responses to mechanical trauma: an experimental study. Surg Neurol. 35:1991;273-279.
58. Kmeciak-Kolada K., Felinska W., Stachura Z., et al. Concentration of biogenic amines and their metabolites in different parts of brain after experimental cerebral concussion. Pol J Pharmacol Pharm. 39:1987;47-53.
59. Hamill R.W., Woolf P.D., McDonald J.V., et al. Catecholamines predict outcome in traumatic brain injury. Ann Neurol. 21:1987;438-443.
60. Woolf P.D., Hamill R.W., Lee L.A., et al. The predictive value of catecholamines in assessing outcome in traumatic brain injury. J Neurosurg. 66:1987;875-882.
61. Donnemiller E., Brenneis C., Wissel J., et al. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med. 27:2000;1410-1414.
62. North R.A. Muscarinic receptors and membrane ion conductances. Trends Pharmacol Sci. 7:(Suppl):1986;19-22.
63. Leonard J.R., Maris D.O., Grady M.S. Fluid percussion injury causes loss of forebrain choline acetyltransferase and nerve growth factor receptor immunoreactive cells in the rat. J Neurotrauma. 11:1994;379-392.
64. Lyeth B.G., Dixon C.E., Jenkins L.W., et al. Effects of scopolamine treatment on long-term behavioral deficits following concussive brain injury to the rat. Brain Res. 452:1988;39-48.
65. Saija A., Robinson S.E., Lyeth B.G., et al. The effects of scopolamine and traumatic brain injury on central cholinergic neurons. J Neurotrauma. 5:1988;161-170.
66. Dixon C.E., Hamm R.J., Taft W.C., et al. Increased anticholinergic sensitivity following closed skull impact and controlled cortical impact traumatic brain injury in the rat. J Neurotrauma. 11:1994;275-287.
67. Dixon C.E., Liu S.J., Jenkins L.W., et al. Time course of increased vulnerability of cholinergic neurotransmission following traumatic brain injury in the rat. Behav Brain Res. 70:1995;125-131.
68. Chen Y., Shohami E., Constantini S., et al. Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. J Neurotrauma. 15:1998;231-237.
69. Pike B.R., Hamm R.J., Temple M.D., et al. Effect of tetrahydroaminocridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury. J Neurotrauma. 14:1997;897-905.
70. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. Giacobini E. Cholinesterases and cholinesterase inhibitors. 2000;181-226 Martin Dunitz, London.
71. Stanislav S.W. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Inj. 11:1997;335-341.
72. Sandel M.E., Olive D.A., Rader M.A. Chlorpromazine-induced psychosis after brain injury. Brain Inj. 7:1993;77-83.
73. Bogdanovitch U.J., Bazarevitch G.J., Kirillov A.L. The use of cholinesterase in severe head injury. Resuscitation. 4:1975;139-141.
74. Eames P., Sutton A. Protracted post-traumatic confusional state treated with physostigmine. Brain Inj. 9:1995;729-734.
75. Goldberg E., Gerstman L.J., Hughes J.E., et al. Selective effects of cholinergic treatment on verbal memory in posttraumatic amnesia. J Clin Neuropsychol. 4:1982;219-234.
76. Levin H.S., Peters B.H., Kalisky Z., et al. Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. Cent Nerv Syst Trauma. 3:1986;333-342.
77. Cardenas D.D., McLean A., Farrell-Roberts L., et al. Oral physostigmine and impaired memory in adults with brain injury. Brain Inj. 8:1994;579-587.
78. Rogers S.L., Friedhoff L.T. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol. 46:1998;1-6.
79. Rogers S.L., Cooper N.M., Sukovaty J.E., et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol. 46:1998;7-12.
80. Taverni J.P., Seliger G., Lichtman S.W. Donepezil mediated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj. 12:1998;77-80.
81. Whelan F.J., Walker M.S., Schultz S.K. Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann Clin Psychiatry. 12:2000;131-135.
82. Masanic C.A., Bayley M.T., VanReekum R., et al. Open-label study of donepezil in traumatic brain injury. Arch Phys Med Rehabil. 82:2001;896-901.
83. Lezak M.D. Subtle sequelae of brain damage: perplexity, distractibility and fatigue. Am J Phys Med. 57:1978;9-15.
84. Adler L.E., Olincy A., Waldo M., et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull. 24:1998;189-202.
85. Baker N., Adler L.E., Franks R.D., et al. Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses. Biol Psychiatry. 22:1987;603-617.
86. Nagamoto H.T., Adler L.E., Waldo M.C., et al. Sensory gating in schizophrenics and normal controls: effects of changing stimulation intervals. Biol Psychiatry. 25:1989;549-561.
87. Boutros N.N., Zouridakis G., Overall J. Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr. 22:1991;40-45.
88. Boutros N., Torello M.W., Burns E.M., et al. Evoked potentials in subjects at risk for Alzheimer's disease. Psychiatry Res. 57:1995;57-63.
89. Boutros N.N., Torello M.W., Barker B.A., et al. The P50 evoked potential component and mismatch detection in normal volunteers: implications for the study of sensory gating. Psychiatry Res. 57:1995;83-88.
90. Boutros N.N., Belger A., Campbell D., et al. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Res. 88:1999;119-133.
91. Adler L.E., Freedman R., Ross R.G., et al. Elementary phenotypes in the neurobiological and genetic study of schizophrenia. Biol Psychiatry. 46:1999;8-18.
92. Adler LE, Nagamoto H, Drebing C, Bronson J. Impaired auditory sensory gating in patients with 20 years of combat post-traumatic stress disorder and depression. American Psychiatric Association Annual Meeting New Research Program and Abstracts, New Orleans, 1991.
93. Nagamoto H.T., Adler L.E., Hea R.A., et al. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry. 40:1996;181-188.
94. Nagamoto H.T., Adler L.E., Waldo M.C., et al. Gating of auditory response in schizophrenics and normal controls: effects of recording site and stimulation interval on the P50 wave. Schizophr Res. 4:1991;31-40.
95. Waldo M.C., Cawthra E., Adler L.E., et al. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophr Res. 12:1994;93-106.
96. Rund B.R., Zeiner P., Sundet K., et al. No vigilance deficit found in either young schizophrenic of ADHD subjects. Scand J Psychol. 39:1998;101-107.
97. Seidman L.J., Biederman J., Weber W., et al. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry. 44:1998;260-268.
98. Mesulam M.-M. From sensation to cognition. Brain. 121:1998;1013-1052.
99. Jellinger K., Seitelberger F. Protracted post-traumatic encephalopathy: pathology, pathogenesis and clinical implications. J Neurol Sci. 10:1970;51-94.
100. Salazar A.M., Grafman J.H., Vance S.C. Consciousness and amnesia after penetrating head injury: neurology and anatomy. Neurology. 36:1986;178-187.
101. Watson M.R., Fenton G.W., McClelland R.J., et al. The post-concussional state: neurophysiologic aspects. Br J Psychiatry. 167:1995;514-521.
102. Naatanen R. Attention and brain function. 1992;Lawrence Erlbaum Associates, Hillsdale, NJ.
103. Gorman L.K., Fu K., Hovda D.A., et al. Effects of traumatic brain injury on the cholinergic system in the rat. J Neurotrauma. 13:1996;457-463.
104. Mesulam M.-M. Attention, confusional states, and neglect. Mesulam M.-M. Principles of behavioral neurology. 1985;125-168 FA Davis, Philadelphia.
105. Filley C.M. Neurobehavioral aspects of cerebral white matter disorders. Fogel B.S., Schiffer R.B., Rao S.M. Neuropsychiatry. 1996;913-933 Williams & Wilkins, Baltimore.
106. Filley C.M. The behavioral neurology of cerebral white matter. Neurology. 50:1998;1535-1540.
107. Bickford P., Nagamoto H.T., Johnson R., et al. Auditory sensory gating in hippocampal neurons: a model system in the rat. Biol Psychiatry. 27:1990;183-192.
108. Bickford-Wimer P.C., Nagamoto H., Johnson R., et al. Auditory sensory gating in hippocampal systems: a model system in the rat. Biol Psychiatry. 27:1989;183-192.
109. Breese C.R., Adams C., Logel J., et al. Comparison of the regional expression of nicotinic acetylcholine receptor alpha-7 mRNA and 125 alpha-bungarotoxin binding in human postmortem brain. J Comp Neurol. 387:1997;385-398.
110. Luntz-Leybman V., Bickford P., Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 587:1992;130-136.
111. Stevens K.E., Freedman R., Collins A.C., et al. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology. 15:1996;152-162.
112. Adler L.E., Hoffer L.J., Griffith J., et al. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 32:1992;607-616.
113. Adler L.E., Hoffer L., Nagamoto H.T., et al. Yohimbine impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacology. 10:1994;249-257.
114. Freedman R., Wetmore C., Stromberg I., et al. Alpha-bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth factor expression. J Neurosci. 13:1993;1965-1975.
115. Cave C.B., Squire L.R. Intact verbal and nonverbal short-term memory following damage to the human hippocampus. Hippocampus. 2:1992;151-163.
116. Cullum C.M., Harris J.G., Waldo M.C., et al. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res. 10:1993;131-141.
117. Griffith J., Hoffer L.D., Adler L.E., et al. Effects of sound intensity on a midlatency evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Psychophysiology. 32:1995;460-466.
118. Harris J.G., Adler L.E., Young D.A., et al. Neuropsychological dysfunction in schizophrenia. Schizophr Res. 20:1996;253-260.
119. Johnson M.R., Adler L.E. Transient impairment in P50 auditory senosry gating induced by a cold-pressor test. Biol Psychiatry. 33:1993;380-387.
120. Ward P.B., Hoffer L.D., Liebert B.J., et al. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res. 64:1996;121-135.
121. Buchwald J.S., Erwin R.J., Read S., et al. Midlatency auditory evoked responses: differential abnormality of P1 in Alzheimer's disease. Electroencephalogr Clin Neurophysiol. 74:1989;378-384.
122. Erwin R.J., Turetsky B.I., Moberg P., et al. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr Res. 33:1998;157-167.
123. Clementz B.A., Blumenfeld L.D., Cobb S. The gamma band response may account for poor P50 suppression in schizophrenia. Neuroreport. 8:1997;3889-3893.
124. Clementz B.A., Geyer M.A., Braff D.L. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophr Res. 30:1998;71-80.
125. Clementz B.A., Geyer M.A., Braff D.L. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry. 155:1998;1691-1694.
126. Light G.A., Geyer M.A., Clementz B.A., et al. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry. 157:2000;767-771.
127. Jin Y., Bunney W.E., Sandman C.A., et al. Is P50 suppression a measure of sensory gating in schizophrenia? Biol Psychiatry. 43:1998;873-878.
128. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry. 49:1992;206-215.
129. Reite M., Teale P., Zimmerman J., et al. Source origin of a 50-msec latency auditory evoked field component in young schizophrenic men. Biol Psychiatry. 24:1988;495-506.
130. Knight R.T., Scabini D., Woods D.L., et al. The effects of lesions of superior temporal gyrus and inferior parietal lobe on temporal and vertex components of the human. AEP. Electroencephalogr Clin Neurophysiol. 70:1988;499-509.
131. Chen B.M., Buchwald J.S. Midlatency auditory evoked responses: differential effects of sleep in the cat. Electroencephalogr Clin Neurophysiol. 65:1986;373-382.
132. Hinman C.L., Buchwald J.S. Depth evoked potential and single unit correlates of vertex midlatency auditory evoked responses. Brain Res. 264:1983;57-67.
133. Woods D.L., Clayworth C.C., Knight R.T., et al. Generators of middle- and long-latency auditory evoked potentials: implications from studies of patients with bitemporal lesions. Electroencephalogr Clin Neurophysiol. 68:1987;195-199.
134. Goff W.R., Williamson P.D., VanGilder J.C., et al. Neural origins of long latency evoked potentials recorded from the depth and from the cortical surface of the brain in man. Prog Clin Neurophysiol. 7:1980;126-145.
135. Wilson C.L., Babb T.L., Halgren E., et al. Habituation of human limbic neuronal response to sensory stimulation. Exp Neurol. 84:1984;74-97.
136. Simpson G.V., Knight R.T. Multiple brain systems generating the rat auditory evoked potential: II. dissociation of auditory cortex and non-lemniscal generator systems. Brain Res. 602:1993;263.
137. Nagamoto H.T., Adler L.E., McRae K.A., et al. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4hydroxyphenylglycol. Neuropsychobiology. 39:1999;10-17.
138. Adler L.E., Gerhardt G., Franks R., et al. Sensory physiology and catecholamines in schizophrenia and mania. Psychiatry Res. 31:(3):1990;297-309.
139. Baker N.J., Staunton M., Adler L.E., et al. Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups. Biol Psychiatry. 27:1990;519-528.
140. American Congress of Rehabilitation Medicine. Definition of mild traumatic brain injury. J Head Trauma Rehabil. 8:1993;86-87.
141. Olincy A., Ross R.G., Harris J.G., et al. The P50 auditory event-evoked potential in adult attention-deficit disorder: comparison with schizophrenia. Biol Psychiatry. 47:2000;969-977.
142. Nitsch R.M., Rossner S., Albrecht C., et al. Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter. J Physiol (Paris). 92:1998;257-264.
143. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition:1994;American Psychiatric Association, Washington, DC.